表紙
市場調査レポート

東部ウマ脳炎 : パイプライン分析

Eastern Equine Encephalitis - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 321904
出版日 ページ情報 英文 31 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
東部ウマ脳炎 : パイプライン分析 Eastern Equine Encephalitis - Pipeline Review, H2 2015
出版日: 2015年08月12日 ページ情報: 英文 31 Pages
概要

東部ウマ脳炎は、蚊が媒介となる感染症であり、アルボウイルスである東部ウマ脳炎ウイルスが原因です。発熱、頭痛等の軽度な症状から、錯乱・失見識・こん睡など重篤なものまで広い症状が現れます。

当レポートでは、東部ウマ脳炎に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

東部ウマ脳炎の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究所別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究所別

治療薬の開発に従事している企業

  • AlphaVax, Inc.
  • AltraVax Inc.
  • EpiVax, Inc.
  • Profectus BioSciences, Inc.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 分子タイプ別

薬剤のプロファイル

  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • equine encephalitis vaccine
  • TSI-GSD-104

開発休止中のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7038IDB

Summary

Global Markets Direct's, 'Eastern Equine Encephalitis - Pipeline Review, H2 2015', provides an overview of the Eastern Equine Encephalitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Eastern Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eastern Equine Encephalitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Eastern Equine Encephalitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Eastern Equine Encephalitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Eastern Equine Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Eastern Equine Encephalitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Eastern Equine Encephalitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Eastern Equine Encephalitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eastern Equine Encephalitis Overview
  • Therapeutics Development
    • Pipeline Products for Eastern Equine Encephalitis - Overview
    • Pipeline Products for Eastern Equine Encephalitis - Comparative Analysis
  • Eastern Equine Encephalitis - Therapeutics under Development by Companies
  • Eastern Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
  • Eastern Equine Encephalitis - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Eastern Equine Encephalitis - Products under Development by Companies
  • Eastern Equine Encephalitis - Products under Investigation by Universities/Institutes
  • Eastern Equine Encephalitis - Companies Involved in Therapeutics Development
    • AlphaVax, Inc.
    • AltraVax Inc.
    • EpiVax, Inc.
    • Profectus BioSciences, Inc.
  • Eastern Equine Encephalitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • equine encephalitis vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TSI-GSD-104 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Eastern Equine Encephalitis - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Eastern Equine Encephalitis, H2 2015
  • Number of Products under Development for Eastern Equine Encephalitis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Eastern Equine Encephalitis - Pipeline by AlphaVax, Inc., H2 2015
  • Eastern Equine Encephalitis - Pipeline by AltraVax Inc., H2 2015
  • Eastern Equine Encephalitis - Pipeline by EpiVax, Inc., H2 2015
  • Eastern Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Eastern Equine Encephalitis - Dormant Projects, H2 2015

List of Figures

  • Number of Products under Development for Eastern Equine Encephalitis, H2 2015
  • Number of Products under Development for Eastern Equine Encephalitis - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top